Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage I Breast Cancer AJCC v6 Clear all
Completed Phase 1Phase 2 Interventional Results available

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

NCT00699491
View directory record Official record
Conditions
Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
192
States / cities
Palo Alto, California • Pleasanton, California • Aurora, Colorado + 123 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Jun 25, 2026, 3:57 PM EDT
Active, not recruiting Phase 3 Interventional

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT04457596
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
1160
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 3:57 PM EDT
Terminated Not applicable Interventional

Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

NCT01050075
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
acupuncture therapy, questionnaire administration, management of therapy complications
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jun 25, 2026, 3:57 PM EDT
Active, not recruiting Not applicable Interventional

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study

NCT05568472
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Interventions
Best Practice, Biospecimen Collection, Endocrine Drug Therapy, Health Education, Questionnaire Administration, Symptom Specific Assessment Tool
Other · Procedure · Behavioral
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
489
States / cities
Kingman, Arizona • Phoenix, Arizona • Antioch, California + 333 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Phase 3 Interventional Results available

S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy

NCT01385137
View directory record Official record
Conditions
Arthralgia, Breast Cancer, Pain
Interventions
omega-3 fatty acid, placebo
Dietary Supplement · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
292
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 215 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Jun 25, 2026, 3:57 PM EDT
Recruiting Not applicable Interventional

Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer

NCT05677802
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Negative Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Medical Chart Review, Stress Management Therapy, Survey Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

NCT00003357
View directory record Official record
Conditions
Breast Cancer
Interventions
GM2-KLH vaccine, QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Phase 3 Interventional

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

NCT00002967
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
106
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 25, 2026, 3:57 PM EDT
Recruiting Phase 2 Interventional

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

NCT07044310
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, Bone Mineral Density Test, Questionnaire Administration, WBF-038
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jun 25, 2026, 3:57 PM EDT
Terminated Not applicable Interventional

Improving Communication With Patients With Breast Cancer

NCT00276822
View directory record Official record
Conditions
Breast Cancer
Interventions
communication intervention
Other
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jun 25, 2026, 3:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer

NCT00086749
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jun 25, 2026, 3:57 PM EDT
Terminated Phase 2 Interventional Results available

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

NCT04249622
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Best Practice, Questionnaire Administration, Rifaximin
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jun 25, 2026, 3:57 PM EDT
Recruiting Phase 2 Interventional

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

NCT06954831
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
Interventions
Cone-Beam Computed Tomography, Hypofractionated External Beam Radiation Therapy, Questionnaire Administration, Radiation Boost, Whole Breast Irradiation
Procedure · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years and older · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Arcadia, California • Duarte, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Phase 2 Interventional

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

NCT00416403
View directory record Official record
Conditions
Breast Cancer
Interventions
fluvastatin sodium, Breast Cancer Surgery Only - Arm III
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

NCT04593277
View directory record Official record
Conditions
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Malignant Neoplasm, Leukemia, Lymphoma, Malignant Solid Neoplasm, Sarcoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Thyroid Gland Carcinoma
Interventions
Internet Mobile Technology, Internet-Based Intervention, Questionnaire Administration, Supportive Care, Informational Intervention
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Phase 2 Interventional

Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer

NCT00244959
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, adjuvant therapy
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2013 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

NCT00022074
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Depression, Hot Flashes
Interventions
gabapentin, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
Up to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Not applicable Interventional Results available

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

NCT00436917
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
zoledronic acid, Letrozole as adjuvant therapy
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

NCT01988571
View directory record Official record
Conditions
Breast Cancer, Lymphoma
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 100 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer

NCT00262834
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
vorinostat, conventional surgery
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jun 25, 2026, 3:57 PM EDT
Recruiting No phase listed Observational

Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

NCT05417867
View directory record Official record
Conditions
Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Not applicable Interventional

Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer

NCT00031811
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms, Osteoporosis
Interventions
raloxifene, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Jun 25, 2026, 3:57 PM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer

NCT03345420
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jun 25, 2026, 3:57 PM EDT